Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Target Price at $37.56
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one […]
Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nineteen research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one […]
